急性ST段抬高型心肌梗死患者提前肝素化的疗效评价及风险观察

目的探讨急性ST段抬高型心肌梗死(STEMI)患者提前肝素化的疗效及风险。方法选取2019年5月至2020年5月我院收治的160例STEMI患者作为研究对象,随机分为两组各80例。治疗组给予提前肝素化PCI术治疗,对照组给予常规肝素化PCI术治疗。比较两组的TIMI血流分级、不良事件发生率以及治疗前后的症状评分、 LVEF。结果术后,治疗组的TIMI血流0~1级率低于对照组,3级率高于对照组(P <0.05)。治疗后,两组的症状评分均低于治疗前,LVEF水平均高于治疗前(P<0.05);治疗组的症状评分低于对照组,LVEF水平高于对照组(P <0.05)。治疗组的不良事件发生率低于对照组(P <0.05)。结论 PCI术提前肝素化可以提高灌注效果,有效缓解STEMI患者的病情,改善患者心功能,改善预后,且具有较高的安全性。

Efficacy Evaluation and Risk Observation of Advanced Heparinization in Patients with Acute ST-Segment Elevation MyocardialInfarction

Objective To explore the efficacy and risk of advanced heparinization in patients with acute ST-segment elevation myocardial infarction(STEMI).Methods 160 cases of STEMI patients admitted to our hospital from May 2019 to May 2020 were selected as research objects,and randomly divided into two groups,with 80 cases in each group.The treatment group received PCI treatment with advanced heparinization,and the control group received PCI with routine heparinization.The TIMI blood flow grade,incidence of adverse events,and symptom scores and LVEF before and after treatment were compared between the two groups.Results After surgery,the rate of TIMI blood flow grade 0~1 of the treatment group was lower than that of the control group,and grade 3 rate was higher than that of the control group(P<0.05).After treatment,the symptom scores in both groups were lower than those before treatment,and LVEF levels were higher than those before treatment(P<0.05);The symptom score of the treatment group was lower than that of the control group,and the level of LVEF was higher than that of the control group(P<0.05).The incidence of adverse events of the treatment group was lower than that of the control group(P<0.05).Conclusions Advanced heparinization in PCI can improve the perfusion effect,effectively alleviate the disease condition of STEMI patients,and improve the cardiac function and prognosis of patients,with high safety.